LONDON (ShareCast) - (ShareCast News) - British biotechnology firm Oxford BioDynamics has entered into an initial collaboration with an unnamed US biopharmaceutical company in order to advance both the discovery and development of treatments for abnormal wound healing responses that lead to fibrosis, a pathological feature of most chronic inflammatory diseases.
Under the terms of the collaboration agreement, the North American firm would be granted access to Oxford BioDynamic's EpiSwitch technology for use in the analysis of the structure-function of genome architecture and to provide fresh insight into fibrotic mechanisms, as well as new targets and biomarkers.

The research will support the development of novel therapeutic candidates and next-generation companion diagnostics, enabling patient population stratification for clinical trials.

Christian Hoyer Millar, chief executive officer of Oxford BioDynamics, said, "We are pleased to be collaborating with a major global biopharma company to support the development of potential novel drug candidates, and the identification of patients suitable for a new fibrosis treatment.

"This new collaboration is further evidence of broad adoption of our validated proprietary technology EpiSwitch for practical use in highly challenging therapeutic development programmes," Miller added.

As of 0900 GMT, shares had gained 3.96% to 242.75p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE